^
    Back
    Association details:
    Biomarker:CD79B mutation
    Cancer:Diffuse Large B Cell Lymphoma
    Drug:safimaltib (JNJ-6633) (MALT1 protein inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASH 2020
    Title:

    2091 Discovery of JNJ-67856633: A Novel, First-in-Class MALT1 Protease Inhibitor for the Treatment of B Cell Lymphomas

    Published date:
    11/04/2020
    Excerpt:
    The compound inhibits proliferation of activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL) cell lines bearing CD79b or CARD11 mutations as well as models mimicking resistance to covalent Bruton’s Tyrosine Kinase (BTK) inhibitors.
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR-II 2020
    Title:

    Abstract 5690: Discovery of JNJ-67856633: A novel, first-in-class MALT1 protease inhibitor for the treatment of B cell lymphomas

    Published date:
    05/15/2020
    Excerpt:
    The compound inhibits proliferation of activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL) cell lines bearing CD79b or CARD11 mutations as well as models mimicking resistance to covalent Bruton’s Tyrosine Kinase (BTK) inhibitors.
    DOI:
    10.1158/1538-7445.AM2020-5690